Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 56
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Widespread ribosome stalling in a genome-reduced bacterium and the need for translational quality control

  • Burgos, Raul
  • Weber, Marc
  • Gallo López, Carolina, 1984-
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Trans-translation is a ubiquitous bacterial mechanism of ribosome rescue mediated by a transfer-messenger RNA (tmRNA) that adds a degradation tag to the truncated nascent polypeptide. Here, we characterize this quality control system in a genome-reduced bacterium, Mycoplasma pneumoniae (MPN), and perform a comparative analysis of protein quality control components in slow and fast-growing prokaryotes. We show in vivo that in MPN the sole quality control cytoplasmic protease (Lon) degrades efficiently tmRNA-tagged proteins. Analysis of tmRNA-mutants encoding a tag resistant to proteolysis reveals extensive tagging activity under normal growth. Unlike knockout strains, these mutants are viable demonstrating the requirement of tmRNA-mediated ribosome recycling. Chaperone and Lon steady-state levels maintain proteostasis in these mutants suggesting a model in which co-evolution of Lon and their substrates offer simple mechanisms of regulation without specialized degradation machineries. Finally, comparative analysis shows relative increase in Lon/Chaperone levels in slow-growing bacteria suggesting physiological adaptation to growth demand., This work has been supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under grant agreement 670216 (MYCOCHASSIS), and Conveni La Caixa 2020–2023 (LA CAIXA-EGA, LCF/PR/GN13/10260009). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program from the Generalitat de Catalunya. M.W acknowledges the European Union's Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Proteored, PRB3 and is supported by grant PT17/0019, of the PE I + D + i 2013–2016, funded by ISCIII and ERDF
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

SURE editing: combining oligo-recombineering and programmable insertion/deletion of selection markers to efficiently edit the Mycoplasma pneumoniae genome

  • Piñero-Lambea, Carlos
  • Garcia-Ramallo, Eva
  • Miravet Verde, Samuel, 1992-
  • Burgos, Raul
  • Scarpa, Margherita
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
The development of advanced genetic tools is boosting microbial engineering which can potentially tackle wide-ranging challenges currently faced by our society. Here we present SURE editing, a multi-recombinase engineering rationale combining oligonucleotide recombineering with the selective capacity of antibiotic resistance via transient insertion of selector plasmids. We test this method in Mycoplasma pneumoniae, a bacterium with a very inefficient native recombination machinery. Using SURE editing, we can seamlessly generate, in a single step, a wide variety of genome modifications at high efficiencies, including the largest possible deletion of this genome (30 Kb) and the targeted complementation of essential genes in the deletion of a region of interest. Additional steps can be taken to remove the selector plasmid from the edited area, to obtain markerless or even scarless edits. Of note, SURE editing is compatible with different site-specific recombinases for mediating transient plasmid integration. This battery of selector plasmids can be used to select different edits, regardless of the target sequence, which significantly reduces the cloning load associated to genome engineering projects. Given the proven functionality in several microorganisms of the machinery behind the SURE editing logic, this method is likely to represent a valuable advance for the synthetic biology field., European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program [670216 (MYCOCHASSIS)]; Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (to the EMBL partnership); Centro de Excelencia Severo Ochoa; CERCA Program from the Generalitat de Catalunya; European Union's Horizon 2020 Research; Innovation Program [634942 (MycoSynVac)]; LaCaixa Fundation [Livetherapeutics HR18-00058]; C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’; M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) [CP16/00094].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Bacterial expression of a designed single-chain IL-10 prevents severe lung inflammation

  • Montero-Blay, Ariadna, 1994-
  • Delgado Blanco, Javier
  • Rodriguez-Arce, Irene
  • Lastrucci, Claire
  • Piñero-Lambea, Carlos
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that is active as a swapped domain dimer and is used in bacterial therapy of gut inflammation. IL-10 can be used as treatment of a wide range of pulmonary diseases. Here we have developed a non-pathogenic chassis (CV8) of the human lung bacterium Mycoplasma pneumoniae (MPN) to treat lung diseases. We find that IL-10 expression by MPN has a limited impact on the lung inflammatory response in mice. To solve these issues, we rationally designed a single-chain IL-10 (SC-IL10) with or without surface mutations, using our protein design software (ModelX and FoldX). As compared to the IL-10 WT, the designed SC-IL10 molecules increase the effective expression in MPN four-fold, and the activity in mouse and human cell lines between 10 and 60 times, depending on the cell line. The SC-IL10 molecules expressed in the mouse lung by CV8 in vivo have a powerful anti-inflammatory effect on Pseudomonas aeruginosa lung infection. This rational design strategy could be used to other molecules with immunomodulatory properties used in bacterial therapy., This work has been supported by the European Research Council (ERC) grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Program from the Generalitat de Catalunya, the European Union's Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac). ML-S acknowledges the support of the FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016; reference CP16/00094). We also acknowledge the staff of CRG/UPF Proteomics Unit who is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) unit and is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Comparative "-omics" in mycoplasma pneumoniae clinical isolates reveals key virulence factors

  • Lluch-Senar, Maria 1982-
  • Cozzuto, Luca
  • Cano, Jaime
  • Delgado Blanco, Javier
  • Lloréns Rico, Verónica, 1989-
  • Pereyre, Sabine
  • Bebear, Cécile
  • Serrano Pubull, Luis, 1982-
The human respiratory tract pathogen M. pneumoniae is one of the best characterized minimal bacterium. Until now, two main groups of clinical isolates of this bacterium have been described (types 1 and 2), differing in the sequence of the P1 adhesin gene. Here, we have sequenced the genomes of 23 clinical isolates of M. pneumoniae. Studying SNPs, non-synonymous mutations, indels and genome rearrangements of these 23 strains and 4 previously sequenced ones, has revealed new subclasses in the two main groups, some of them being associated with the country of isolation. Integrative analysis of in vitro gene essentiality and mutation rates enabled the identification of several putative virulence factors and antigenic proteins; revealing recombination machinery, glycerol metabolism and peroxide production as possible factors in the genetics and physiology of these pathogenic strains. Additionally, the transcriptomes and proteomes of two representative strains, one from each of the two main groups, have been characterized to evaluate the impact of mutations on RNA and proteins levels. This study has revealed that type 2 strains show higher expression levels of CARDS toxin, a protein recently shown to be one of the major factors of inflammation. Thus, we propose that type 2 strains could be more toxigenic than type 1 strains of M. pneumoniae., This work was supported by the European Research Council (ERC). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 634942.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

SynMyco transposon: engineering transposon vectors for efficient transformation of minimal genomes

  • Montero-Blay, Ariadna, 1994-
  • Miravet Verde, Samuel, 1992-
  • Lluch-Senar, Maria 1982-
  • Piñero-Lambea, Carlos
  • Serrano Pubull, Luis, 1982-
Mycoplasmas are important model organisms for Systems and Synthetic Biology, and are pathogenic to a wide variety of species. Despite their relevance, many of the tools established for genome editing in other microorganisms are not available for Mycoplasmas. The Tn4001 transposon is the reference tool to work with these bacteria, but the transformation efficiencies (TEs) reported for the different species vary substantially. Here, we explore the mechanisms underlying these differences in four Mycoplasma species, Mycoplasma agalactiae, Mycoplasma feriruminatoris, Mycoplasma gallisepticum and Mycoplasma pneumoniae, selected for being representative members of each cluster of the Mycoplasma genus. We found that regulatory regions (RRs) driving the expression of the transposase and the antibiotic resistance marker have a major impact on the TEs. We then designed a synthetic RR termed SynMyco RR to control the expression of the key transposon vector elements. Using this synthetic RR, we were able to increase the TE for M. gallisepticum, M. feriruminatoris and M. agalactiae by 30-, 980- and 1036-fold, respectively. Finally, to illustrate the potential of this new transposon, we performed the first essentiality study in M. agalactiae, basing our study on more than 199,000 genome insertions., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Integration of multi-omics data of a genome-reduced bacterium: Prevalence of post-transcriptional regulation and its correlation with protein abundances

  • Chen, Wei-Hua
  • van Noort, Vera
  • Lluch-Senar, Maria 1982-
  • Hennrich, Marco L.
  • Wodke, Judith A.H.
  • Yus, Eva
  • Alibés, Andreu
  • Roma, Guglielmo
  • Mende, Daniel R.
  • Pesavento, Christina
  • Typas, Athanasios
  • Gavin, Anne-Claude
  • Serrano Pubull, Luis, 1982-
We developed a comprehensive resource for the genome-reduced bacterium Mycoplasma pneumoniae comprising 1748 consistently generated '-omics' data sets, and used it to quantify the power of antisense non-coding RNAs (ncRNAs), lysine acetylation, and protein phosphorylation in predicting protein abundance (11%, 24% and 8%, respectively). These factors taken together are four times more predictive of the proteome abundance than of mRNA abundance. In bacteria, post-translational modifications (PTMs) and ncRNA transcription were both found to increase with decreasing genomic GC-content and genome size. Thus, the evolutionary forces constraining genome size and GC-content modify the relative contributions of the different regulatory layers to proteome homeostasis, and impact more genomic and genetic features than previously appreciated. Indeed, these scaling principles will enable us to develop more informed approaches when engineering minimal synthetic genomes., The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP7/2007–2013)/ERC Grant Agreement No. 232913. We acknowledge support from the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012–0208. This project has received funding from the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 634942. Funding for open access charge: European Research council (ERC) advanced Grant Agreement No. 232913, the Fundación Marcelino Botin, the Spanish Ministerio de Economía y Competitividad BIO2007-61762, the ISCIII, Subdirección General de evaluación y fomento de la investigación PI10/01702 to the ICREA researcher L.S.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Development of a serum-free medium to aid large-scale production of Mycoplasma-based therapies

  • Burgos, Raul
  • Garcia-Ramallo, Eva
  • Shaw, Daniel, 1993-
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
To assist in the advancement of the large-scale production of safe Mycoplasma vaccines and other Mycoplasma-based therapies, we developed a culture medium free of animal serum and other animal components for Mycoplasma pneumoniae growth. By establishing a workflow method to systematically test different compounds and concentrations, we provide optimized formulations capable of supporting serial passaging and robust growth reaching 60 to 70% of the biomass obtained in rich medium. Global transcriptomic and proteomic analysis showed minor physiological changes upon cell culture in the animal component-free medium, supporting its suitability for the production of M. pneumoniae-based therapies. The major contributors to growth performance were found to be glucose as a carbon source, glycerol, cholesterol, and phospholipids as a source of fatty acids. Bovine serum albumin or cyclodextrin (in the animal component-free medium) were required as lipid carriers to prevent lipid toxicity. Connaught Medical Research Laboratories medium (CMRL) used to simplify medium preparation as a source of amino acids, nucleotide precursors, vitamins, and other cofactors could be substituted by cysteine. In fact, the presence of protein hydrolysates such as yeastolate or peptones was found to be essential and preferred over free amino acids, except for the cysteine. Supplementation of nucleotide precursors and vitamins is not strictly necessary in the presence of yeastolate, suggesting that this animal origin-free hydrolysate serves as an efficient source for these compounds. Finally, we adapted the serum-free medium formulation to support growth of Mycoplasma hyopneumoniae, a swine pathogen for which inactivated whole-cell vaccines are available. IMPORTANCE Mycoplasma infections have a significant negative impact on both livestock production and human health. Vaccination is often the first option to control disease and alleviate the economic impact that some Mycoplasma infections cause on milk production, weight gain, and animal health. The fastidious nutrient requirements of these bacteria, however, challenges the industrial production of attenuated or inactivated whole-cell vaccines, which depends on the use of animal serum and other animal raw materials. Apart from their clinical relevance, some Mycoplasma species have become cellular models for systems and synthetic biology, owing to the small size of their genomes and the absence of a cell wall, which offers unique opportunities for the secretion and delivery of biotherapeutics. This study proposes medium formulations free of serum and animal components with the potential of supporting large-scale production upon industrial optimization, thus contributing to the development of safe vaccines and other Mycoplasma-based therapies., This work has been supported by the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under grant agreement 670216 (MYCOCHASSIS), and Conveni La Caixa 2020-2023 (LA CAIXA-EGA, LCF/PR/GN13/10260009). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program from the Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A reporter system coupled with high-throughput sequencing unveils key bacterial transcription and translation determinants

  • Yus, Eva
  • Yang, Jae-Seong
  • Sogues, Adrià
  • Serrano Pubull, Luis, 1982-
Quantitative analysis of the sequence determinants of transcription and translation regulation is relevant for systems and synthetic biology. To identify these determinants, researchers have developed different methods of screening random libraries using fluorescent reporters or antibiotic resistance genes. Here, we have implemented a generic approach called ELM-seq (expression level monitoring by DNA methylation) that overcomes the technical limitations of such classic reporters. ELM-seq uses DamID (Escherichia coli DNA adenine methylase as a reporter coupled with methylation-sensitive restriction enzyme digestion and high-throughput sequencing) to enable in vivo quantitative analyses of upstream regulatory sequences. Using the genome-reduced bacterium Mycoplasma pneumoniae, we show that ELM-seq has a large dynamic range and causes minimal toxicity. We use ELM-seq to determine key sequences (known and putatively novel) of promoter and untranslated regions that influence transcription and translation efficiency. Applying ELM-seq to other organisms will help us to further understand gene expression and guide synthetic biology.Quantitative analysis of how DNA sequence determines transcription and translation regulation is of interest to systems and synthetic biologists. Here the authors present ELM-seq, which uses Dam activity as reporter for high-throughput analysis of promoter and 5'-UTR regions., We thank the CRG/UPF Proteomics Unit that is part of the Plataforma de Recursos Biomoleculares y Bioinformáticos (Instituto de Salud Carlos III), supported by grant PT13/0001. The project was supported by funds from the Fundación Marcelino Botin and the Spanish Ministerio de Economía y Competitividad (BIO2007-61762). This project was financed by Instituto de Salud Carlos III and co-financed by Federación Española de Enfermedades Raras under grant agreement PI10/01702 and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program, under grant agreement Nos 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). We acknowledge support from the Spanish Ministry of Economy and Competitiveness, Centro de Excelencia Severo Ochoa 2013-2017 and the support given by Juan de la Cierva-Incorporación Program (IJCI‐2014‐22070) to J.S.Y. We also acknowledge the support of the CERCA Program/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A genetic toolkit and gene switches to limit Mycoplasma growth for biosafety applications

  • Broto, Alicia
  • Gaspari, Erika
  • Miravet Verde, Samuel, 1992-
  • Martins dos Santos, Vitor
  • Isalan, Mark
Mycoplasmas have exceptionally streamlined genomes and are strongly adapted to their many hosts, which provide them with essential nutrients. Owing to their relative genomic simplicity, Mycoplasmas have been used to develop chassis for biotechnological applications. However, the dearth of robust and precise toolkits for genomic manipulation and tight regulation has hindered any substantial advance. Herein we describe the construction of a robust genetic toolkit for M. pneumoniae, and its successful deployment to engineer synthetic gene switches that control and limit Mycoplasma growth, for biosafety containment applications. We found these synthetic gene circuits to be stable and robust in the long-term, in the context of a minimal cell. With this work, we lay a foundation to develop viable and robust biosafety systems to exploit a synthetic Mycoplasma chassis for live attenuated vectors for therapeutic applications., This work was funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634942 (MycoSynVac)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Protein quality control and regulated proteolysis in the genome-reduced organism mycoplasma pneumoniae

  • Burgos, Raul
  • Weber, Marc
  • Martínez, Sira
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Protein degradation is a crucial cellular process in all-living systems. Here, using Mycoplasma pneumoniae as a model organism, we defined the minimal protein degradation machinery required to maintain proteome homeostasis. Then, we conditionally depleted the two essential ATP-dependent proteases. Whereas depletion of Lon results in increased protein aggregation and decreased heat tolerance, FtsH depletion induces cell membrane damage, suggesting a role in quality control of membrane proteins. An integrative comparative study combining shotgun proteomics and RNA-seq revealed 62 and 34 candidate substrates, respectively. Cellular localization of substrates and epistasis studies supports separate functions for Lon and FtsH. Protein half-life measurements also suggest a role for Lon-modulated protein decay. Lon plays a key role in protein quality control, degrading misfolded proteins and those not assembled into functional complexes. We propose that regulating complex assembly and degradation of isolated proteins is a mechanism that coordinates important cellular processes like cell division. Finally, by considering the entire set of proteases and chaperones, we provide a fully integrated view of how a minimal cell regulates protein folding and degradation., This work has been supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program from the Generalitat de Catalunya. M.W acknowledges the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac) and M.L.‐S. The support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D+i 2013‐2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

LoxTnSeq: random transposon insertions combined with cre/lox recombination and counterselection to generate large random genome reductions

  • Shaw, Daniel, 1993-
  • Miravet Verde, Samuel, 1992-
  • Piñero-Lambea, Carlos
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
The removal of unwanted genetic material is a key aspect in many synthetic biology efforts and often requires preliminary knowledge of which genomic regions are dispensable. Typically, these efforts are guided by transposon mutagenesis studies, coupled to deepsequencing (TnSeq) to identify insertion points and gene essentiality. However, epistatic interactions can cause unforeseen changes in essentiality after the deletion of a gene, leading to the redundancy of these essentiality maps. Here, we present LoxTnSeq, a new methodology to generate and catalogue libraries of genome reduction mutants. LoxTnSeq combines random integration of lox sites by transposon mutagenesis, and the generation of mutants via Cre recombinase, catalogued via deep sequencing. When LoxTnSeq was applied to the naturally genome reduced bacterium Mycoplasma pneumoniae, we obtained a mutant pool containing 285 unique deletions. These deletions spanned from > 50 bp to 28 Kb, which represents 21% of the total genome. LoxTnSeq also highlighted large regions of non-essential genes that could be removed simultaneously, and other non-essential regions that could not, providing a guide for future genome reductions., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Model-driven design allows growth of Mycoplasma pneumoniae on serum-free media

  • Gaspari, Erika
  • Malachowski, Antoni
  • García Morales, Luis
  • Burgos, Raul
  • Serrano Pubull, Luis, 1982-
  • Martins dos Santos, Vitor
  • Suarez-Diez, Maria
Mycoplasma pneumoniae is a slow-growing, human pathogen that causes atypical pneumonia. Because it lacks a cell wall, many antibiotics are ineffective. Due to its reduced genome and dearth of many biosynthetic pathways, this fastidious bacterium depends on rich, undefined medium for growth, which makes large-scale cultivation challenging and expensive. To understand factors limiting growth, we developed a genome-scale, constraint-based model of M. pneumoniae called iEG158_mpn to describe the metabolic potential of this bacterium. We have put special emphasis on cell membrane formation to identify key lipid components to maximize bacterial growth. We have used this knowledge to predict essential components validated with in vitro serum-free media able to sustain growth. Our findings also show that glycolysis and lipid metabolism are much less efficient under hypoxia; these findings suggest that factors other than metabolism and membrane formation alone affect the growth of M. pneumoniae. Altogether, our modelling approach allowed us to optimize medium composition, enabled growth in defined media and streamlined operational requirements, thereby providing the basis for stable, reproducible and less expensive production., This work has received funding from European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under grant agreement no. 634942 (MycoSynVac) and no. 670216 (MYCOCHASSIS).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Impact of C-terminal amino acid composition on protein expression in bacteria

  • Weber, Marc
  • Burgos, Raul
  • Yus, Eva
  • Yang, Jae-Seong
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
The C-terminal sequence of a protein is involved in processes such as efficiency of translation termination and protein degradation. However, the general relationship between features of this C-terminal sequence and levels of protein expression remains unknown. Here, we identified C-terminal amino acid biases that are ubiquitous across the bacterial taxonomy (1,582 genomes). We showed that the frequency is higher for positively charged amino acids (lysine, arginine), while hydrophobic amino acids and threonine are lower. We then studied the impact of C-terminal composition on protein levels in a library of Mycoplasma pneumoniae mutants, covering all possible combinations of the two last codons. We found that charged and polar residues, in particular lysine, led to higher expression, while hydrophobic and aromatic residues led to lower expression, with a difference in protein levels up to fourfold. We further showed that modulation of protein degradation rate could be one of the main mechanisms driving these differences. Our results demonstrate that the identity of the last amino acids has a strong influence on protein expression levels., This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). ML-S acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Defined chromosome structure in the genome-reduced bacterium Mycoplasma pneumoniae

  • Trussart, Marie, 1985-
  • Yus, Eva
  • Martínez, Sira
  • Baù, Davide
  • Tahara, Yuhei O.
  • Pengo, Thomas
  • Widjaja, Michael
  • Kretschmer, Simon
  • Swoger, Jim
  • Djordjevic, Steven P.
  • Turnbull, Lynne
  • Whitchurch, Cynthia B.
  • Miyata, Makoto
  • Martí Renom, Marc A.
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
DNA-binding proteins are central regulators of chromosome organization; however, in genome-reduced bacteria their diversity is largely diminished. Whether the chromosomes of such bacteria adopt defined three-dimensional structures remains unexplored. Here we combine Hi-C and super-resolution microscopy to determine the structure of the Mycoplasma pneumoniae chromosome at a 10 kb resolution. We find a defined structure, with a global symmetry between two arms that connect opposite poles, one bearing the chromosomal Ori and the other the midpoint. Analysis of local structures at a 3 kb resolution indicates that the chromosome is organized into domains ranging from 15 to 33 kb. We provide evidence that genes within the same domain tend to be co-regulated, suggesting that chromosome organization influences transcriptional regulation, and that supercoiling regulates local organization. This study extends the current understanding of bacterial genome organization and demonstrates that a defined chromosomal structure is a universal feature of living systems., The research leading to these results was funded by the European Union Seventh Framework Programme (FP7/2007-2013 to L.S.), through the European Research Council, under grant agreement 232913 to L.S. and 609989 to M.A.M-R., the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 634942 to L.S, the Fundación Botín to L.S., the Spanish Ministry of Economy and Competitiveness (BIO2007-61762 to L.S. and BFU2013-47736-P to M.A.M.-R., the National Plan of R+D+i, the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación- (PI10/01702 to L.S.), the Human Frontiers Science Program (RGP0044 to M.A.M.-R.), the ERASynBio/MINECO Grant PCIN-2015-125 to L.S, and the European Regional Development Fund (ERDF) to L.S. We acknowledge support from the Spanish Ministry of Economy and Competitiveness, 'Centro de Excelencia Severo Ochoa 2013-2017' (SEV-2012-0208). We acknowledge the support of the CERCA Programme / Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

  • Garrido, Victoria
  • Piñero-Lambea, Carlos
  • Rodriguez-Arce, Irene
  • Paetzold, Bernhard, 1981-
  • Ferrar, Tony
  • Weber, Marc
  • Garcia-Ramallo, Eva
  • Gallo López, Carolina, 1984-
  • Collantes, María
  • Peñuelas, Iván
  • Serrano Pubull, Luis, 1982-
  • Grilló, María-Jesús
  • Lluch-Senar, Maria 1982-
Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo. We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro, ex vivo, and in vivo. To our knowledge, this is the first engineered genome-reduced bacterium that can fight against clinically relevant biofilm-associated bacterial infections., This work has been supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac), and the La Caixa Fundation grant (Livetherapeutics HR18-00058). M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). We also acknowledge the staff of CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) unit is a member of the ProteoRed PRB3 consortium, which is supported by grant PT17/0019 of the PE I + D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Insights into the Mechanisms of Basal Coordination of Transcription Using a Genome-Reduced Bacterium

  • Junier, Ivan
  • Unal, E. Besray
  • Yus, Eva
  • Lloréns Rico, Verónica, 1989-
  • Serrano Pubull, Luis, 1982-
Coordination of transcription in bacteria occurs at supra-operonic scales, but the extent, specificity, and mechanisms of such regulation are poorly understood. Here, we tackle this problem by profiling the transcriptome of the model organism Mycoplasma pneumoniae across 115 growth conditions. We identify three qualitatively different levels of co-expression corresponding to distinct relative orientations and intergenic properties of adjacent genes. We reveal that the degree of co-expression between co-directional adjacent operons, and more generally between genes, is tightly related to their capacity to be transcribed en bloc into the same mRNA. We further show that this genome-wide pervasive transcription of adjacent genes and operons is specifically repressed by DNA regions preferentially bound by RNA polymerases, by intrinsic terminators, and by large intergenic distances. Taken together, our findings suggest that the basal coordination of transcription is mediated by the physical entities and mechanical properties of the transcription process itself, and that operon-like behaviors may strongly vary from condition to condition., This work was supported by Fundación Marcelino Botin and the Spanish Ministerio de Economía y Competitividad (BIO2007-61762). This project was financed by Instituto de Salud Carlos III and co-financed by Federación Española de Enfermedades Raras under grant agreement PI10/01702 and the European Research Council and European Union’s Horizon 2020 research and innovation program under grant agreements 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). The Centre for Genomic Regulation acknowledges the support of the Spanish Ministry of Economy and Competitiveness, “Centro de Excelencia Severo Ochoa 2013-2017,” SEV-2012-0208.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mycoplasma pneumoniae genome editing based on oligo recombineering and Cas9-mediated counterselection

  • Piñero-Lambea, Carlos
  • Garcia-Ramallo, Eva
  • Martínez, Sira
  • Delgado Blanco, Javier
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
Mycoplasma species share a set of features, such as lack of a cell wall, streamlined genomes, simplified metabolism, and the use of a deviant genetic code, that make them attractive approximations of what a chassis strain should ideally be. Among them, Mycoplasma pneumoniae arises as a candidate for synthetic biology projects, as it is one of the most deeply characterized bacteria. However, the historical paucity of tools for editing Mycoplasma genomes has precluded the establishment of M. pneumoniae as a suitable chassis strain. Here, we developed an oligonucleotide recombineering method for this strain based on GP35, a ssDNA recombinase originally encoded by a Bacillus subtilis-associated phage. GP35-mediated oligo recombineering is able to carry out point mutations in the M. pneumoniae genome with an efficiency as high as 2.7 × 10-2, outperforming oligo recombineering protocols developed for other bacteria. Gene deletions of different sizes showed a decreasing power trend between efficiency and the scale of the attempted edition. However, the editing rates for all modifications increased when CRISPR/Cas9 was used to counterselect nonedited cells. This allowed edited clones carrying chromosomal deletions of up to 1.8 kb to be recovered with little to no screening of survivor cells. We envision this technology as a major step toward the use of M. pneumoniae, and possibly other Mycoplasmas, as synthetic biology chassis strains., This project has received funding from the European Union’s Horizon 2020 research and innovation program under Grant 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under Grant 670216 (MYCOCHASSIS) and the FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). We also acknowledge support of the Spanish Ministry of Science and Innovation, to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. Finally, we would like to thank Dr. Sarah A. Head for critical manuscript revision.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Determination of the gene regulatory network of a genome-reduced bacterium highlights alternative regulation independent of transcription factors

  • Yus, Eva
  • Lloréns Rico, Verónica, 1989-
  • Martínez, Sira
  • Gallo López, Carolina, 1984-
  • Eilers, Hinnerk
  • Blötz, Cedric
  • Stülke, Jörg
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Here, we determined the relative importance of different transcriptional mechanisms in the genome-reduced bacterium Mycoplasma pneumoniae, by employing an array of experimental techniques under multiple genetic and environmental perturbations. Of the 143 genes tested (21% of the bacterium's annotated proteins), only 55% showed an altered phenotype, highlighting the robustness of biological systems. We identified nine transcription factors (TFs) and their targets, representing 43% of the genome, and 16 regulators that indirectly affect transcription. Only 20% of transcriptional regulation is mediated by canonical TFs when responding to perturbations. Using a Random Forest, we quantified the non-redundant contribution of different mechanisms such as supercoiling, metabolic control, RNA degradation, and chromosome topology to transcriptional changes. Model-predicted gene changes correlate well with experimental data in 95% of the tested perturbations, explaining up to 70% of the total variance when also considering noise. This analysis highlights the importance of considering non-TF-mediated regulation when engineering bacteria., The project was supported by funds from the Fundación Marcelino Botín and the Spanish Ministerio de Economía y Competitividad (BIO2007-61762). This project was financed by Instituto de Salud Carlos III and co-financed by Federación Española de Enfermedades Raras under grant agreement PI10/01702 and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreements no 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). We acknowledge support from the Spanish Ministry of Economy and Competitiveness to the EMBL partnership, Centro de Excelencia Severo Ochoa.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Rescuing discarded spectra: full comprehensive analysis of a minimal proteome

  • Lluch-Senar, Maria 1982-
  • Mancuso, Francesco M.
  • Climente González, Héctor
  • Peña Paz, Marcia I.
  • Sabidó Aguadé, Eduard, 1981-
  • Serrano Pubull, Luis, 1982-
A common problem encountered when performing large-scale MS proteome analysis is the loss of information due to the high percentage of unassigned spectra. To determine the causes behind this loss we have analyzed the proteome of one of the smallest living bacteria that can be grown axenically, Mycoplasma pneumoniae (729 ORFs). The proteome of M. pneumoniae cells, grown in defined media, was analyzed by MS. An initial search with both Mascot and a species-specific NCBInr database with common contaminants (NCBImpn), resulted in around 79% of the acquired spectra not having an assignment. The percentage of non-assigned spectra was reduced to 27% after re-analysis of the data with the PEAKS software, thereby increasing the proteome coverage of M. pneumoniae from the initial 60% to over 76%. Nonetheless, 33 413 spectra with assigned amino acid sequences could not be mapped to any NCBInr database protein sequence. Approximately, 1% of these unassigned peptides corresponded to PTMs and 4% to M. pneumoniae protein variants (deamidation and translation inaccuracies). The most abundant peptide sequence variants (Phe-Tyr and Ala-Ser) could be explained by alterations in the editing capacity of the corresponding tRNA synthases. About another 1% of the peptides not associated to any protein had repetitions of the same aromatic/hydrophobic amino acid at the N-terminus, or had Arg/Lys at the C-terminus. Thus, in a model system, we have maximized the number of assigned spectra to 73% (51 453 out of the 70 040 initial acquired spectra)., This work was sup-ported by the European Research Council (ERC), the Fundación Marcelino Botín, the Spanish Ministerio de Economía y Com-petitividad BIO2007-61762 and the ISCIII (PI10/01702). TheCRG/UPF Proteomics Unit is part of the “Plataforma de Re-cursos Biomoleculares y Bioinform´aticos (ProteoRed)” supportedby grant PT13/0001 of Instituto de Salud Carlos III (ISCIII).We acknowledge the support of the Spanish Ministry of Economyand Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012-0208. This project has received funding fromthe European Union’s Horizon 2020 research and innovationprogram under grant agreement No 634942
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms

  • Mazzolini, Rocco
  • Rodríguez-Arce, Irene
  • Fernández-Barat, Laia
  • Piñero-Lambea, Carlos
  • Garrido, Victoria
  • Rebollada-Merino, Agustín
  • Motos, Ana
  • Torres, Antoni
  • Grilló, María-Jesús
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
Engineered live bacteria could provide a new modality for treating lung infections, a major cause of mortality worldwide. In the present study, we engineered a genome-reduced human lung bacterium, Mycoplasma pneumoniae, to treat ventilator-associated pneumonia, a disease with high hospital mortality when associated with Pseudomonas aeruginosa biofilms. After validating the biosafety of an attenuated M. pneumoniae chassis in mice, we introduced four transgenes into the chromosome by transposition to implement bactericidal and biofilm degradation activities. We show that this engineered strain has high efficacy against an acute P. aeruginosa lung infection in a mouse model. In addition, we demonstrated that the engineered strain could dissolve biofilms formed in endotracheal tubes of patients with ventilator-associated pneumonia and be combined with antibiotics targeting the peptidoglycan layer to increase efficacy against Gram-positive and Gram-negative bacteria. We expect our M. pneumoniae-engineered strain to be able to treat biofilm-associated infections in the respiratory tract., This work was supported by the European Research Council under the European Union’s Horizon 2020 research and innovation program, under grant agreement no. 670216 (MYCOCHASSIS). We thank the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 Research and Innovation Programme, grant no. 634942 (MycoSynVac), La Caixa Health (HR18-00058), CB 06/06/0028/CIBER de enfermedades respiratorias-Ciberes and ICREA Academy/Institució Catalana de Recerca i Estudis Avançats, 2.603/IDIBAPS, SGR/Generalitat de Catalunya for their support. M.L.-S. thanks the funder Instituto de Salud Carlos III (ISCIII, Acción Estratégica en Salud 2016, FEDER project, reference CP16/00094) for support of the research of this work. We also thank the staff of the CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies unit and a member of the ProteoRed PRB3 consortium, supported by grant no. PT17/0019 of the PE I+D+i 2013–2016 from the ISCIII and European Regional Development Fund.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A RAGE based strategy for the genome engineering of the human respiratory pathogen mycoplasma pneumoniae

  • García Morales, Luis
  • Ruiz, Estelle
  • Gourgues, Géraldine
  • Rideau, Fabien
  • Piñero-Lambea, Carlos
  • Lluch-Senar, Maria 1982-
  • Blanchard, Alain
  • Lartigue, Carole
Genome engineering of microorganisms has become a standard in microbial biotechnologies. Several efficient tools are available for the genetic manipulation of model bacteria such as Escherichia coli and Bacillus subtilis, or the yeast Saccharomyces cerevisiae. Difficulties arise when transferring these tools to nonmodel organisms. Synthetic biology strategies relying on genome transplantation (GT) aim at using yeast cells for engineering bacterial genomes cloned as artificial chromosomes. However, these strategies remain unsuccessful for many bacteria, including Mycoplasma pneumoniae (MPN), a human pathogen infecting the respiratory tract that has been extensively studied as a model for systems biology of simple unicellular organisms. Here, we have designed a novel strategy for genome engineering based on the recombinase-assisted genomic engineering (RAGE) technology for editing the MPN genome. Using this strategy, we have introduced a 15 kbp fragment at a specific locus of the MPN genome and replaced 38 kbp from its genome by engineered versions modified either in yeast or in E. coli. A strain harboring a synthetic version of this fragment cleared of 13 nonessential genes could also be built and propagated in vitro. These strains were depleted of known virulence factors aiming at creating an avirulent chassis for SynBio applications. Such a chassis and technology are a step forward to build vaccines or deliver therapeutic compounds in the lungs to prevent or cure respiratory diseases in humans., The authors thank Clara Blanchard for English proofreading. We also thank Dr. Don L. Court for providing biological material and advice. We acknowledge the financial support by the European Union’s Horizon 2020 research and innovation program under Grant Agreement [No. 634942]; and the European MiniCell project selected by ANR, in the frame of the ERASynBio second Joint Call for Transnational Research Projects [No. ANR-15-SYNB-0001-04].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

CReasPy-Cloning: a method for simultaneous cloning and engineering of megabase-sized genomes in yeast using the CRISPR-Cas9 system.

  • Ruiz, Estelle
  • Talenton, Vincent
  • Dubrana, Marie-Pierre
  • Guesdon, Gabrielle
  • Lluch-Senar, Maria 1982-
  • Salin, Franck
  • Sirand-Pugnet, Pascal
  • Arfi, Yonathan
  • Lartigue, Carole
Over the past decade, a new strategy was developed to bypass the difficulties to genetically engineer some microbial species by transferring (or "cloning") their genome into another organism that is amenable to efficient genetic modifications and therefore acts as a living workbench. As such, the yeast Saccharomyces cerevisiae has been used to clone and engineer genomes from viruses, bacteria, and algae. The cloning step requires the insertion of yeast genetic elements in the genome of interest, in order to drive its replication and maintenance as an artificial chromosome in the host cell. Current methods used to introduce these genetic elements are still unsatisfactory, due either to their random nature (transposon) or the requirement for unique restriction sites at specific positions (TAR cloning). Here we describe the CReasPy-cloning, a new method that combines both the ability of Cas9 to cleave DNA at a user-specified locus and the yeast's highly efficient homologous recombination to simultaneously clone and engineer a bacterial chromosome in yeast. Using the 0.816 Mbp genome of Mycoplasma pneumoniae as a proof of concept, we demonstrate that our method can be used to introduce the yeast genetic element at any location in the bacterial chromosome while simultaneously deleting various genes or group of genes. We also show that CReasPy-cloning can be used to edit up to three independent genomic loci at the same time with an efficiency high enough to warrant the screening of a small (<50) number of clones, allowing for significantly shortened genome engineering cycle times., This work is part of the European MiniCell project “A model-driven approach to minimal cell engineering for medical therapy” selected by ANR, in the frame of the ERASynBio second Joint Call for Transnational Research Projects (No. ANR-15-SYNB-0001-04). It has also been supported by the National Science Foundation (Grant No. IOS-1110151) and the European Union’s Horizon 2020 research and innovation program under Grant Agreement No. 634942.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Lox'd in translation: contradictions in the nomenclature surrounding common lox-site mutants and their implications in experiments

  • Shaw, Daniel, 1993-
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
The Cre-Lox system is a highly versatile and powerful DNA recombinase mechanism, mainly used in genetic engineering to insert or remove desired DNA sequences. It is widely utilized across multiple fields of biology, with applications ranging from plants, to mammals, to microbes. A key feature of this system is its ability to allow recombination between mutant lox sites. Two of the most commonly used mutant sites are named lox66 and lox71, which recombine to create a functionally inactive double mutant lox72 site. However, a large portion of the published literature has incorrectly annotated these mutant lox sites, which in turn can lead to difficulties in replication of methods, design of proper vectors and confusion over the proper nomenclature. Here, we demonstrate common errors in annotations, the impacts they can have on experimental viability, and a standardized naming convention. We also show an example of how this incorrect annotation can induce toxic effects in bacteria that lack optimal DNA repair systems, exemplified by Mycoplasma pneumoniae., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Inferring active metabolic pathways from proteomics and essentiality data

  • Montero-Blay, Ariadna, 1994-
  • Piñero-Lambea, Carlos
  • Miravet Verde, Samuel, 1992-
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Here, we propose an approach to identify active metabolic pathways by integrating gene essentiality analysis and protein abundance. We use two bacterial species (Mycoplasma pneumoniae and Mycoplasma agalactiae) that share a high gene content similarity yet show significant metabolic differences. First, we build detailed metabolic maps of their carbon metabolism, the most striking difference being the absence of two key enzymes for glucose metabolism in M. agalactiae. We then determine carbon sources that allow growth in M. agalactiae, and we introduce glucose-dependent growth to show the functionality of its remaining glycolytic enzymes. By analyzing gene essentiality and performing quantitative proteomics, we can predict the active metabolic pathways connected to carbon metabolism and show significant differences in use and direction of key pathways despite sharing the large majority of genes. Gene essentiality combined with quantitative proteomics and metabolic maps can be used to determine activity and directionality of metabolic pathways., This project was financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement nos. 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme / Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

  • Garrido, Victoria
  • Piñero-Lambea, Carlos
  • Rodríguez-Arce, Irene
  • Paetzold, Bernhard
  • Ferrar, Tony
  • Weber, Marc
  • García-Ramallo, Eva
  • Gallo, Carolina
  • Collantes, María
  • Peñuelas, Iván
  • Serrano, Luis
  • Grilló, María Jesús
  • Lluch-Senar, María
Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo. We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro, ex vivo, and in vivo. To our knowledge, this is the first engineered genome-reduced bacterium that can fight against clinically relevant biofilm-associated bacterial infections., This work has been supported by the European Research Council (ERC) underthe European Union’s Horizon2020research and innovation program, undergrant agreement 670216(MYCOCHASSIS). We also acknowledge the support ofthe Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to theEMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Programfrom the Generalitat de Catalunya, the European Union’s Horizon2020research and innovation program under grant agreement 634942 (Myco-SynVac), and the LaCaixa Fundation grant (Livetherapeutics HR18-00058).M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III(ISCIII, Accion Estrategica en Salud2016) (reference CP16/00094). We alsoacknowledge the staff of CRG/UPF Proteomics Unit, which is part of the Span-ish Infrastructure for Omics Technologies (ICTS OmicsTech) unit is a memberof the ProteoRed PRB3consortium, which is supported by grant PT17/0019ofthe PE I+D+i2013-2016from the Instituto de Salud Carlos III (ISCIII) and ERDF. We also acknowledge Margarita Ecay for her assistance in the PETimages analysis and Samuel Miravet-Verde for the bioinformatic support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms

  • Mazzolini, Rocco
  • Rodríguez-Arce, Irene
  • Fernández-Barat, Laia
  • Piñero-Lambea, Carlos
  • Garrido, Victoria
  • Rebollada-Merino, Agustín
  • Motos, Anna
  • Torres, Antoni
  • Grilló, María Jesús
  • Serrano, Luis
  • Lluch-Senar, Maria
Engineered live bacteria could provide a new modality for treating lung infections, a major cause of mortality worldwide. In the present study, we engineered a genome-reduced human lung bacterium, Mycoplasma pneumoniae, to treat ventilator-associated pneumonia, a disease with high hospital mortality when associated with Pseudomonas aeruginosa biofilms. After validating the biosafety of an attenuated M. pneumoniae chassis in mice, we introduced four transgenes into the chromosome by transposition to implement bactericidal and biofilm degradation activities. We show that this engineered strain has high efficacy against an acute P. aeruginosa lung infection in a mouse model. In addition, we demonstrated that the engineered strain could dissolve biofilms formed in endotracheal tubes of patients with ventilator-associated pneumonia and be combined with antibiotics targeting the peptidoglycan layer to increase efficacy against Gram-positive and Gram-negative bacteria. We expect our M. pneumoniae-engineered strain to be able to treat biofilm-associated infections in the respiratory tract., This work was supported by the European Research Council under the European Union’s Horizon 2020 research and innovation program, under grant agreement no. 670216 (MYCOCHASSIS). We thank the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 Research and Innovation Programme, grant no. 634942 (MycoSynVac), La Caixa Health (HR18-00058), CB 06/06/0028/CIBER de enfermedades respiratorias-Ciberes and ICREA Academy/Institució Catalana de Recerca i Estudis Avançats, 2.603/IDIBAPS, SGR/Generalitat de Catalunya for their support. M.L.-S. thanks the funder Instituto de Salud Carlos III (ISCIII, Acción Estratégica en Salud 2016, FEDER project, reference CP16/00094) for support of the research of this work. We also thank the staff of the CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies unit and a member of the ProteoRed PRB3 consortium, supported by grant no. PT17/0019 of the PE I+D+i 2013–2016 from the ISCIII and European Regional Development Fund., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integration of multi-omics data of a genome-reduced bacterium: Prevalence of post-transcriptional regulation and its correlation with protein abundances

  • Chen, Wei-Hua
  • van Noort, Vera
  • Lluch-Senar, Maria 1982-
  • Hennrich, Marco L.
  • Wodke, Judith A.H.
  • Yus, Eva
  • Alibés, Andreu
  • Roma, Guglielmo
  • Mende, Daniel R.
  • Pesavento, Christina
  • Typas, Athanasios
  • Gavin, Anne-Claude
  • Serrano Pubull, Luis, 1982-
We developed a comprehensive resource for the genome-reduced bacterium Mycoplasma pneumoniae comprising 1748 consistently generated '-omics' data sets, and used it to quantify the power of antisense non-coding RNAs (ncRNAs), lysine acetylation, and protein phosphorylation in predicting protein abundance (11%, 24% and 8%, respectively). These factors taken together are four times more predictive of the proteome abundance than of mRNA abundance. In bacteria, post-translational modifications (PTMs) and ncRNA transcription were both found to increase with decreasing genomic GC-content and genome size. Thus, the evolutionary forces constraining genome size and GC-content modify the relative contributions of the different regulatory layers to proteome homeostasis, and impact more genomic and genetic features than previously appreciated. Indeed, these scaling principles will enable us to develop more informed approaches when engineering minimal synthetic genomes., The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP7/2007–2013)/ERC Grant Agreement No. 232913. We acknowledge support from the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012–0208. This project has received funding from the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 634942. Funding for open access charge: European Research council (ERC) advanced Grant Agreement No. 232913, the Fundación Marcelino Botin, the Spanish Ministerio de Economía y Competitividad BIO2007-61762, the ISCIII, Subdirección General de evaluación y fomento de la investigación PI10/01702 to the ICREA researcher L.S.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparative "-omics" in mycoplasma pneumoniae clinical isolates reveals key virulence factors

  • Lluch-Senar, Maria 1982-
  • Cozzuto, Luca
  • Cano, Jaime
  • Delgado Blanco, Javier
  • Lloréns Rico, Verónica, 1989-
  • Pereyre, Sabine
  • Bebear, Cécile
  • Serrano Pubull, Luis, 1982-
The human respiratory tract pathogen M. pneumoniae is one of the best characterized minimal bacterium. Until now, two main groups of clinical isolates of this bacterium have been described (types 1 and 2), differing in the sequence of the P1 adhesin gene. Here, we have sequenced the genomes of 23 clinical isolates of M. pneumoniae. Studying SNPs, non-synonymous mutations, indels and genome rearrangements of these 23 strains and 4 previously sequenced ones, has revealed new subclasses in the two main groups, some of them being associated with the country of isolation. Integrative analysis of in vitro gene essentiality and mutation rates enabled the identification of several putative virulence factors and antigenic proteins; revealing recombination machinery, glycerol metabolism and peroxide production as possible factors in the genetics and physiology of these pathogenic strains. Additionally, the transcriptomes and proteomes of two representative strains, one from each of the two main groups, have been characterized to evaluate the impact of mutations on RNA and proteins levels. This study has revealed that type 2 strains show higher expression levels of CARDS toxin, a protein recently shown to be one of the major factors of inflammation. Thus, we propose that type 2 strains could be more toxigenic than type 1 strains of M. pneumoniae., This work was supported by the European Research Council (ERC). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 634942.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Model-driven design allows growth of Mycoplasma pneumoniae on serum-free media

  • Gaspari, Erika
  • Malachowski, Antoni
  • García Morales, Luis
  • Burgos, Raul
  • Serrano Pubull, Luis, 1982-
  • Martins dos Santos, Vitor
  • Suarez-Diez, Maria
Mycoplasma pneumoniae is a slow-growing, human pathogen that causes atypical pneumonia. Because it lacks a cell wall, many antibiotics are ineffective. Due to its reduced genome and dearth of many biosynthetic pathways, this fastidious bacterium depends on rich, undefined medium for growth, which makes large-scale cultivation challenging and expensive. To understand factors limiting growth, we developed a genome-scale, constraint-based model of M. pneumoniae called iEG158_mpn to describe the metabolic potential of this bacterium. We have put special emphasis on cell membrane formation to identify key lipid components to maximize bacterial growth. We have used this knowledge to predict essential components validated with in vitro serum-free media able to sustain growth. Our findings also show that glycolysis and lipid metabolism are much less efficient under hypoxia; these findings suggest that factors other than metabolism and membrane formation alone affect the growth of M. pneumoniae. Altogether, our modelling approach allowed us to optimize medium composition, enabled growth in defined media and streamlined operational requirements, thereby providing the basis for stable, reproducible and less expensive production., This work has received funding from European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under grant agreement no. 634942 (MycoSynVac) and no. 670216 (MYCOCHASSIS).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impact of C-terminal amino acid composition on protein expression in bacteria

  • Weber, Marc
  • Burgos, Raul
  • Yus, Eva
  • Yang, Jae-Seong
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
The C-terminal sequence of a protein is involved in processes such as efficiency of translation termination and protein degradation. However, the general relationship between features of this C-terminal sequence and levels of protein expression remains unknown. Here, we identified C-terminal amino acid biases that are ubiquitous across the bacterial taxonomy (1,582 genomes). We showed that the frequency is higher for positively charged amino acids (lysine, arginine), while hydrophobic amino acids and threonine are lower. We then studied the impact of C-terminal composition on protein levels in a library of Mycoplasma pneumoniae mutants, covering all possible combinations of the two last codons. We found that charged and polar residues, in particular lysine, led to higher expression, while hydrophobic and aromatic residues led to lower expression, with a difference in protein levels up to fourfold. We further showed that modulation of protein degradation rate could be one of the main mechanisms driving these differences. Our results demonstrate that the identity of the last amino acids has a strong influence on protein expression levels., This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). ML-S acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A reporter system coupled with high-throughput sequencing unveils key bacterial transcription and translation determinants

  • Yus, Eva
  • Yang, Jae-Seong
  • Sogues, Adrià
  • Serrano Pubull, Luis, 1982-
Quantitative analysis of the sequence determinants of transcription and translation regulation is relevant for systems and synthetic biology. To identify these determinants, researchers have developed different methods of screening random libraries using fluorescent reporters or antibiotic resistance genes. Here, we have implemented a generic approach called ELM-seq (expression level monitoring by DNA methylation) that overcomes the technical limitations of such classic reporters. ELM-seq uses DamID (Escherichia coli DNA adenine methylase as a reporter coupled with methylation-sensitive restriction enzyme digestion and high-throughput sequencing) to enable in vivo quantitative analyses of upstream regulatory sequences. Using the genome-reduced bacterium Mycoplasma pneumoniae, we show that ELM-seq has a large dynamic range and causes minimal toxicity. We use ELM-seq to determine key sequences (known and putatively novel) of promoter and untranslated regions that influence transcription and translation efficiency. Applying ELM-seq to other organisms will help us to further understand gene expression and guide synthetic biology.Quantitative analysis of how DNA sequence determines transcription and translation regulation is of interest to systems and synthetic biologists. Here the authors present ELM-seq, which uses Dam activity as reporter for high-throughput analysis of promoter and 5'-UTR regions., We thank the CRG/UPF Proteomics Unit that is part of the Plataforma de Recursos Biomoleculares y Bioinformáticos (Instituto de Salud Carlos III), supported by grant PT13/0001. The project was supported by funds from the Fundación Marcelino Botin and the Spanish Ministerio de Economía y Competitividad (BIO2007-61762). This project was financed by Instituto de Salud Carlos III and co-financed by Federación Española de Enfermedades Raras under grant agreement PI10/01702 and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program, under grant agreement Nos 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). We acknowledge support from the Spanish Ministry of Economy and Competitiveness, Centro de Excelencia Severo Ochoa 2013-2017 and the support given by Juan de la Cierva-Incorporación Program (IJCI‐2014‐22070) to J.S.Y. We also acknowledge the support of the CERCA Program/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

LoxTnSeq: random transposon insertions combined with cre/lox recombination and counterselection to generate large random genome reductions

  • Shaw, Daniel
  • Miravet-Verde, Samuel
  • Piñero Lambea, Carlos
  • Serrano, Luis
  • Lluch, Maria
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya., The removal of unwanted genetic material is a key aspect in many synthetic biology efforts and often requires preliminary knowledge of which genomic regions are dispensable. Typically, these efforts are guided by transposon mutagenesis studies, coupled to deepsequencing (TnSeq) to identify insertion points and gene essentiality. However, epistatic interactions can cause unforeseen changes in essentiality after the deletion of a gene, leading to the redundancy of these essentiality maps. Here, we present LoxTnSeq, a new methodology to generate and catalogue libraries of genome reduction mutants. LoxTnSeq combines random integration of lox sites by transposon mutagenesis, and the generation of mutants via Cre recombinase, catalogued via deep sequencing. When LoxTnSeq was applied to the naturally genome reduced bacterium Mycoplasma pneumoniae, we obtained a mutant pool containing 285 unique deletions. These deletions spanned from > 50 bp to 28 Kb, which represents 21% of the total genome. LoxTnSeq also highlighted large regions of non-essential genes that could be removed simultaneously, and other non-essential regions that could not, providing a guide for future genome reductions., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inferring active metabolic pathways from proteomics and essentiality data

  • Montero-Blay, Ariadna, 1994-
  • Piñero-Lambea, Carlos
  • Miravet Verde, Samuel, 1992-
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Here, we propose an approach to identify active metabolic pathways by integrating gene essentiality analysis and protein abundance. We use two bacterial species (Mycoplasma pneumoniae and Mycoplasma agalactiae) that share a high gene content similarity yet show significant metabolic differences. First, we build detailed metabolic maps of their carbon metabolism, the most striking difference being the absence of two key enzymes for glucose metabolism in M. agalactiae. We then determine carbon sources that allow growth in M. agalactiae, and we introduce glucose-dependent growth to show the functionality of its remaining glycolytic enzymes. By analyzing gene essentiality and performing quantitative proteomics, we can predict the active metabolic pathways connected to carbon metabolism and show significant differences in use and direction of key pathways despite sharing the large majority of genes. Gene essentiality combined with quantitative proteomics and metabolic maps can be used to determine activity and directionality of metabolic pathways., This project was financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement nos. 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme / Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SURE editing: combining oligo-recombineering and programmable insertion/deletion of selection markers to efficiently edit the Mycoplasma pneumoniae genome

  • Piñero Lambea, Carlos
  • Eva, Garcia-Ramallo
  • Miravet-Verde, Samuel
  • Burgos, Raul
  • Scarpa, Margherita
  • Serrano, Luis
  • Lluch, Maria
European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program [670216 (MYCOCHASSIS)]; Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (to the EMBL partnership); Centro de Excelencia Severo Ochoa; CERCA Program from the Generalitat de Catalunya; European Union’s Horizon 2020 Research; Innovation Program [634942 (MycoSynVac)]; LaCaixa Fundation [Livetherapeutics HR18-00058]; C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’; M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Accion Estratégica en Salud 2016) ´[CP16/00094]. Conflict of interest statement. None declared., The development of advanced genetic tools is boosting microbial engineering which can potentially tackle wide-ranging challenges currently faced by our society. Here we present SURE editing, a multi-recombinase engineering rationale combining oligonucleotide recombineering with the selective capacity of antibiotic resistance via transient insertion of selector plasmids. We test this method in Mycoplasma pneumoniae, a bacterium with a very inefficient native recombination machinery. Using SURE editing, we can seamlessly generate, in a single step, a wide variety of genome modifications at high efficiencies, including the largest possible deletion of this genome (30 Kb) and the targeted complementation of essential genes in the deletion of a region of interest. Additional steps can be taken to remove the selector plasmid from the edited area, to obtain markerless or even scarless edits. Of note, SURE editing is compatible with different site-specific recombinases for mediating transient plasmid integration. This battery of selector plasmids can be used to select different edits, regardless of the target sequence, which significantly reduces the cloning load associated to genome engineering projects. Given the proven functionality in several microorganisms of the machinery behind the SURE editing logic, this method is likely to represent a valuable advance for the synthetic biology field., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

  • Garrido, Victoria
  • Piñero-Lambea, Carlos
  • Rodriguez-Arce, Irene
  • Paetzold, Bernhard, 1981-
  • Ferrar, Tony
  • Weber, Marc
  • Garcia-Ramallo, Eva
  • Gallo López, Carolina, 1984-
  • Collantes, María
  • Peñuelas, Iván
  • Serrano Pubull, Luis, 1982-
  • Grilló, María-Jesús
  • Lluch-Senar, Maria 1982-
Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo. We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro, ex vivo, and in vivo. To our knowledge, this is the first engineered genome-reduced bacterium that can fight against clinically relevant biofilm-associated bacterial infections., This work has been supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac), and the La Caixa Fundation grant (Livetherapeutics HR18-00058). M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). We also acknowledge the staff of CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) unit is a member of the ProteoRed PRB3 consortium, which is supported by grant PT17/0019 of the PE I + D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lox'd in translation: contradictions in the nomenclature surrounding common lox-site mutants and their implications in experiments

  • Shaw, Daniel, 1993-
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
The Cre-Lox system is a highly versatile and powerful DNA recombinase mechanism, mainly used in genetic engineering to insert or remove desired DNA sequences. It is widely utilized across multiple fields of biology, with applications ranging from plants, to mammals, to microbes. A key feature of this system is its ability to allow recombination between mutant lox sites. Two of the most commonly used mutant sites are named lox66 and lox71, which recombine to create a functionally inactive double mutant lox72 site. However, a large portion of the published literature has incorrectly annotated these mutant lox sites, which in turn can lead to difficulties in replication of methods, design of proper vectors and confusion over the proper nomenclature. Here, we demonstrate common errors in annotations, the impacts they can have on experimental viability, and a standardized naming convention. We also show an example of how this incorrect annotation can induce toxic effects in bacteria that lack optimal DNA repair systems, exemplified by Mycoplasma pneumoniae., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mycoplasma pneumoniae genome editing based on oligo recombineering and Cas9-mediated counterselection

  • Piñero-Lambea, Carlos
  • Garcia-Ramallo, Eva
  • Martínez, Sira
  • Delgado Blanco, Javier
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
Mycoplasma species share a set of features, such as lack of a cell wall, streamlined genomes, simplified metabolism, and the use of a deviant genetic code, that make them attractive approximations of what a chassis strain should ideally be. Among them, Mycoplasma pneumoniae arises as a candidate for synthetic biology projects, as it is one of the most deeply characterized bacteria. However, the historical paucity of tools for editing Mycoplasma genomes has precluded the establishment of M. pneumoniae as a suitable chassis strain. Here, we developed an oligonucleotide recombineering method for this strain based on GP35, a ssDNA recombinase originally encoded by a Bacillus subtilis-associated phage. GP35-mediated oligo recombineering is able to carry out point mutations in the M. pneumoniae genome with an efficiency as high as 2.7 × 10-2, outperforming oligo recombineering protocols developed for other bacteria. Gene deletions of different sizes showed a decreasing power trend between efficiency and the scale of the attempted edition. However, the editing rates for all modifications increased when CRISPR/Cas9 was used to counterselect nonedited cells. This allowed edited clones carrying chromosomal deletions of up to 1.8 kb to be recovered with little to no screening of survivor cells. We envision this technology as a major step toward the use of M. pneumoniae, and possibly other Mycoplasmas, as synthetic biology chassis strains., This project has received funding from the European Union’s Horizon 2020 research and innovation program under Grant 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under Grant 670216 (MYCOCHASSIS) and the FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). We also acknowledge support of the Spanish Ministry of Science and Innovation, to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. Finally, we would like to thank Dr. Sarah A. Head for critical manuscript revision.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Insights into the Mechanisms of Basal Coordination of Transcription Using a Genome-Reduced Bacterium

  • Junier, Ivan
  • Unal, E. Besray
  • Yus, Eva
  • Lloréns Rico, Verónica, 1989-
  • Serrano Pubull, Luis, 1982-
Coordination of transcription in bacteria occurs at supra-operonic scales, but the extent, specificity, and mechanisms of such regulation are poorly understood. Here, we tackle this problem by profiling the transcriptome of the model organism Mycoplasma pneumoniae across 115 growth conditions. We identify three qualitatively different levels of co-expression corresponding to distinct relative orientations and intergenic properties of adjacent genes. We reveal that the degree of co-expression between co-directional adjacent operons, and more generally between genes, is tightly related to their capacity to be transcribed en bloc into the same mRNA. We further show that this genome-wide pervasive transcription of adjacent genes and operons is specifically repressed by DNA regions preferentially bound by RNA polymerases, by intrinsic terminators, and by large intergenic distances. Taken together, our findings suggest that the basal coordination of transcription is mediated by the physical entities and mechanical properties of the transcription process itself, and that operon-like behaviors may strongly vary from condition to condition., This work was supported by Fundación Marcelino Botin and the Spanish Ministerio de Economía y Competitividad (BIO2007-61762). This project was financed by Instituto de Salud Carlos III and co-financed by Federación Española de Enfermedades Raras under grant agreement PI10/01702 and the European Research Council and European Union’s Horizon 2020 research and innovation program under grant agreements 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). The Centre for Genomic Regulation acknowledges the support of the Spanish Ministry of Economy and Competitiveness, “Centro de Excelencia Severo Ochoa 2013-2017,” SEV-2012-0208.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

LoxTnSeq: random transposon insertions combined with cre/lox recombination and counterselection to generate large random genome reductions

  • Shaw, Daniel, 1993-
  • Miravet Verde, Samuel, 1992-
  • Piñero-Lambea, Carlos
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
The removal of unwanted genetic material is a key aspect in many synthetic biology efforts and often requires preliminary knowledge of which genomic regions are dispensable. Typically, these efforts are guided by transposon mutagenesis studies, coupled to deepsequencing (TnSeq) to identify insertion points and gene essentiality. However, epistatic interactions can cause unforeseen changes in essentiality after the deletion of a gene, leading to the redundancy of these essentiality maps. Here, we present LoxTnSeq, a new methodology to generate and catalogue libraries of genome reduction mutants. LoxTnSeq combines random integration of lox sites by transposon mutagenesis, and the generation of mutants via Cre recombinase, catalogued via deep sequencing. When LoxTnSeq was applied to the naturally genome reduced bacterium Mycoplasma pneumoniae, we obtained a mutant pool containing 285 unique deletions. These deletions spanned from > 50 bp to 28 Kb, which represents 21% of the total genome. LoxTnSeq also highlighted large regions of non-essential genes that could be removed simultaneously, and other non-essential regions that could not, providing a guide for future genome reductions., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development of a serum-free medium to aid large-scale production of Mycoplasma-based therapies

  • Burgos, Raul
  • Garcia-Ramallo, Eva
  • Shaw, Daniel, 1993-
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
To assist in the advancement of the large-scale production of safe Mycoplasma vaccines and other Mycoplasma-based therapies, we developed a culture medium free of animal serum and other animal components for Mycoplasma pneumoniae growth. By establishing a workflow method to systematically test different compounds and concentrations, we provide optimized formulations capable of supporting serial passaging and robust growth reaching 60 to 70% of the biomass obtained in rich medium. Global transcriptomic and proteomic analysis showed minor physiological changes upon cell culture in the animal component-free medium, supporting its suitability for the production of M. pneumoniae-based therapies. The major contributors to growth performance were found to be glucose as a carbon source, glycerol, cholesterol, and phospholipids as a source of fatty acids. Bovine serum albumin or cyclodextrin (in the animal component-free medium) were required as lipid carriers to prevent lipid toxicity. Connaught Medical Research Laboratories medium (CMRL) used to simplify medium preparation as a source of amino acids, nucleotide precursors, vitamins, and other cofactors could be substituted by cysteine. In fact, the presence of protein hydrolysates such as yeastolate or peptones was found to be essential and preferred over free amino acids, except for the cysteine. Supplementation of nucleotide precursors and vitamins is not strictly necessary in the presence of yeastolate, suggesting that this animal origin-free hydrolysate serves as an efficient source for these compounds. Finally, we adapted the serum-free medium formulation to support growth of Mycoplasma hyopneumoniae, a swine pathogen for which inactivated whole-cell vaccines are available. IMPORTANCE Mycoplasma infections have a significant negative impact on both livestock production and human health. Vaccination is often the first option to control disease and alleviate the economic impact that some Mycoplasma infections cause on milk production, weight gain, and animal health. The fastidious nutrient requirements of these bacteria, however, challenges the industrial production of attenuated or inactivated whole-cell vaccines, which depends on the use of animal serum and other animal raw materials. Apart from their clinical relevance, some Mycoplasma species have become cellular models for systems and synthetic biology, owing to the small size of their genomes and the absence of a cell wall, which offers unique opportunities for the secretion and delivery of biotherapeutics. This study proposes medium formulations free of serum and animal components with the potential of supporting large-scale production upon industrial optimization, thus contributing to the development of safe vaccines and other Mycoplasma-based therapies., This work has been supported by the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under grant agreement 670216 (MYCOCHASSIS), and Conveni La Caixa 2020-2023 (LA CAIXA-EGA, LCF/PR/GN13/10260009). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program from the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Widespread ribosome stalling in a genome-reduced bacterium and the need for translational quality control

  • Burgos, Raul
  • Weber, Marc
  • Gallo López, Carolina, 1984-
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Trans-translation is a ubiquitous bacterial mechanism of ribosome rescue mediated by a transfer-messenger RNA (tmRNA) that adds a degradation tag to the truncated nascent polypeptide. Here, we characterize this quality control system in a genome-reduced bacterium, Mycoplasma pneumoniae (MPN), and perform a comparative analysis of protein quality control components in slow and fast-growing prokaryotes. We show in vivo that in MPN the sole quality control cytoplasmic protease (Lon) degrades efficiently tmRNA-tagged proteins. Analysis of tmRNA-mutants encoding a tag resistant to proteolysis reveals extensive tagging activity under normal growth. Unlike knockout strains, these mutants are viable demonstrating the requirement of tmRNA-mediated ribosome recycling. Chaperone and Lon steady-state levels maintain proteostasis in these mutants suggesting a model in which co-evolution of Lon and their substrates offer simple mechanisms of regulation without specialized degradation machineries. Finally, comparative analysis shows relative increase in Lon/Chaperone levels in slow-growing bacteria suggesting physiological adaptation to growth demand., This work has been supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under grant agreement 670216 (MYCOCHASSIS), and Conveni La Caixa 2020–2023 (LA CAIXA-EGA, LCF/PR/GN13/10260009). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program from the Generalitat de Catalunya. M.W acknowledges the European Union's Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Proteored, PRB3 and is supported by grant PT17/0019, of the PE I + D + i 2013–2016, funded by ISCIII and ERDF
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A RAGE based strategy for the genome engineering of the human respiratory pathogen mycoplasma pneumoniae

  • García Morales, Luis
  • Ruiz, Estelle
  • Gourgues, Géraldine
  • Rideau, Fabien
  • Piñero-Lambea, Carlos
  • Lluch-Senar, Maria 1982-
  • Blanchard, Alain
  • Lartigue, Carole
Genome engineering of microorganisms has become a standard in microbial biotechnologies. Several efficient tools are available for the genetic manipulation of model bacteria such as Escherichia coli and Bacillus subtilis, or the yeast Saccharomyces cerevisiae. Difficulties arise when transferring these tools to nonmodel organisms. Synthetic biology strategies relying on genome transplantation (GT) aim at using yeast cells for engineering bacterial genomes cloned as artificial chromosomes. However, these strategies remain unsuccessful for many bacteria, including Mycoplasma pneumoniae (MPN), a human pathogen infecting the respiratory tract that has been extensively studied as a model for systems biology of simple unicellular organisms. Here, we have designed a novel strategy for genome engineering based on the recombinase-assisted genomic engineering (RAGE) technology for editing the MPN genome. Using this strategy, we have introduced a 15 kbp fragment at a specific locus of the MPN genome and replaced 38 kbp from its genome by engineered versions modified either in yeast or in E. coli. A strain harboring a synthetic version of this fragment cleared of 13 nonessential genes could also be built and propagated in vitro. These strains were depleted of known virulence factors aiming at creating an avirulent chassis for SynBio applications. Such a chassis and technology are a step forward to build vaccines or deliver therapeutic compounds in the lungs to prevent or cure respiratory diseases in humans., The authors thank Clara Blanchard for English proofreading. We also thank Dr. Don L. Court for providing biological material and advice. We acknowledge the financial support by the European Union’s Horizon 2020 research and innovation program under Grant Agreement [No. 634942]; and the European MiniCell project selected by ANR, in the frame of the ERASynBio second Joint Call for Transnational Research Projects [No. ANR-15-SYNB-0001-04].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Determination of the gene regulatory network of a genome-reduced bacterium highlights alternative regulation independent of transcription factors

  • Yus, Eva
  • Lloréns Rico, Verónica, 1989-
  • Martínez, Sira
  • Gallo López, Carolina, 1984-
  • Eilers, Hinnerk
  • Blötz, Cedric
  • Stülke, Jörg
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Here, we determined the relative importance of different transcriptional mechanisms in the genome-reduced bacterium Mycoplasma pneumoniae, by employing an array of experimental techniques under multiple genetic and environmental perturbations. Of the 143 genes tested (21% of the bacterium's annotated proteins), only 55% showed an altered phenotype, highlighting the robustness of biological systems. We identified nine transcription factors (TFs) and their targets, representing 43% of the genome, and 16 regulators that indirectly affect transcription. Only 20% of transcriptional regulation is mediated by canonical TFs when responding to perturbations. Using a Random Forest, we quantified the non-redundant contribution of different mechanisms such as supercoiling, metabolic control, RNA degradation, and chromosome topology to transcriptional changes. Model-predicted gene changes correlate well with experimental data in 95% of the tested perturbations, explaining up to 70% of the total variance when also considering noise. This analysis highlights the importance of considering non-TF-mediated regulation when engineering bacteria., The project was supported by funds from the Fundación Marcelino Botín and the Spanish Ministerio de Economía y Competitividad (BIO2007-61762). This project was financed by Instituto de Salud Carlos III and co-financed by Federación Española de Enfermedades Raras under grant agreement PI10/01702 and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreements no 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). We acknowledge support from the Spanish Ministry of Economy and Competitiveness to the EMBL partnership, Centro de Excelencia Severo Ochoa.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Protein quality control and regulated proteolysis in the genome-reduced organism mycoplasma pneumoniae

  • Burgos, Raul
  • Weber, Marc
  • Martínez, Sira
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Protein degradation is a crucial cellular process in all-living systems. Here, using Mycoplasma pneumoniae as a model organism, we defined the minimal protein degradation machinery required to maintain proteome homeostasis. Then, we conditionally depleted the two essential ATP-dependent proteases. Whereas depletion of Lon results in increased protein aggregation and decreased heat tolerance, FtsH depletion induces cell membrane damage, suggesting a role in quality control of membrane proteins. An integrative comparative study combining shotgun proteomics and RNA-seq revealed 62 and 34 candidate substrates, respectively. Cellular localization of substrates and epistasis studies supports separate functions for Lon and FtsH. Protein half-life measurements also suggest a role for Lon-modulated protein decay. Lon plays a key role in protein quality control, degrading misfolded proteins and those not assembled into functional complexes. We propose that regulating complex assembly and degradation of isolated proteins is a mechanism that coordinates important cellular processes like cell division. Finally, by considering the entire set of proteases and chaperones, we provide a fully integrated view of how a minimal cell regulates protein folding and degradation., This work has been supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program from the Generalitat de Catalunya. M.W acknowledges the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac) and M.L.‐S. The support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D+i 2013‐2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms

  • Mazzolini, Rocco
  • Rodríguez-Arce, Irene
  • Fernandez Barat, Laia
  • Piñero-Lambea, Carlos
  • Garrido, Victoria
  • Rebollada-Merino, Agustín
  • Motos, Anna
  • Torres, Antonio
  • Grillo, Maria-Jesus
  • Serrano, Luis
  • Lluch, Maria
This work was supported by the European Research Council under the European Union’s Horizon 2020 research and innovation program, under grant agreement no. 670216 (MYCOCHASSIS). We thank the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 Research and Innovation Programme, grant no. 634942 (MycoSynVac), La Caixa Health (HR18-00058), CB 06/06/0028/CIBER de enfermedades respiratorias-Ciberes and ICREA Academy/Institució Catalana de Recerca i Estudis Avançats, 2.603/IDIBAPS, SGR/Generalitat de Catalunya for their support. M.L.-S. thanks the funder Instituto de Salud Carlos III (ISCIII, Acción Estratégica en Salud 2016, FEDER project, reference CP16/00094) for support of the research of this work. We also thank the staf of the CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies unit and a member of the ProteoRed PRB3 consortium, supported by grant no. PT17/0019 of the PE I+D+i 2013–2016 from the ISCIII and European Regional Development Fund., Engineered live bacteria could provide a new modality for treating lung infections, a major cause of mortality worldwide. In the present study, we engineered a genome-reduced human lung bacterium, Mycoplasma pneumoniae, to treat ventilator-associated pneumonia, a disease with high hospital mortality when associated with Pseudomonas aeruginosa biofilms. After validating the biosafety of an attenuated M. pneumoniae chassis in mice, we introduced four transgenes into the chromosome by transposition to implement bactericidal and biofilm degradation activities. We show that this engineered strain has high efficacy against an acute P. aeruginosa lung infection in a mouse model. In addition, we demonstrated that the engineered strain could dissolve biofilms formed in endotracheal tubes of patients with ventilator-associated pneumonia and be combined with antibiotics targeting the peptidoglycan layer to increase efficacy against Gram-positive and Gram-negative bacteria. We expect our M. pneumoniae-engineered strain to be able to treat biofilm-associated infections in the respiratory tract., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SURE editing: combining oligo-recombineering and programmable insertion/deletion of selection markers to efficiently edit the Mycoplasma pneumoniae genome

  • Piñero-Lambea, Carlos
  • Garcia-Ramallo, Eva
  • Miravet Verde, Samuel, 1992-
  • Burgos, Raul
  • Scarpa, Margherita
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
The development of advanced genetic tools is boosting microbial engineering which can potentially tackle wide-ranging challenges currently faced by our society. Here we present SURE editing, a multi-recombinase engineering rationale combining oligonucleotide recombineering with the selective capacity of antibiotic resistance via transient insertion of selector plasmids. We test this method in Mycoplasma pneumoniae, a bacterium with a very inefficient native recombination machinery. Using SURE editing, we can seamlessly generate, in a single step, a wide variety of genome modifications at high efficiencies, including the largest possible deletion of this genome (30 Kb) and the targeted complementation of essential genes in the deletion of a region of interest. Additional steps can be taken to remove the selector plasmid from the edited area, to obtain markerless or even scarless edits. Of note, SURE editing is compatible with different site-specific recombinases for mediating transient plasmid integration. This battery of selector plasmids can be used to select different edits, regardless of the target sequence, which significantly reduces the cloning load associated to genome engineering projects. Given the proven functionality in several microorganisms of the machinery behind the SURE editing logic, this method is likely to represent a valuable advance for the synthetic biology field., European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program [670216 (MYCOCHASSIS)]; Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (to the EMBL partnership); Centro de Excelencia Severo Ochoa; CERCA Program from the Generalitat de Catalunya; European Union's Horizon 2020 Research; Innovation Program [634942 (MycoSynVac)]; LaCaixa Fundation [Livetherapeutics HR18-00058]; C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’; M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) [CP16/00094].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Defined chromosome structure in the genome-reduced bacterium Mycoplasma pneumoniae

  • Trussart, Marie, 1985-
  • Yus, Eva
  • Martínez, Sira
  • Baù, Davide
  • Tahara, Yuhei O.
  • Pengo, Thomas
  • Widjaja, Michael
  • Kretschmer, Simon
  • Swoger, Jim
  • Djordjevic, Steven P.
  • Turnbull, Lynne
  • Whitchurch, Cynthia B.
  • Miyata, Makoto
  • Martí Renom, Marc A.
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
DNA-binding proteins are central regulators of chromosome organization; however, in genome-reduced bacteria their diversity is largely diminished. Whether the chromosomes of such bacteria adopt defined three-dimensional structures remains unexplored. Here we combine Hi-C and super-resolution microscopy to determine the structure of the Mycoplasma pneumoniae chromosome at a 10 kb resolution. We find a defined structure, with a global symmetry between two arms that connect opposite poles, one bearing the chromosomal Ori and the other the midpoint. Analysis of local structures at a 3 kb resolution indicates that the chromosome is organized into domains ranging from 15 to 33 kb. We provide evidence that genes within the same domain tend to be co-regulated, suggesting that chromosome organization influences transcriptional regulation, and that supercoiling regulates local organization. This study extends the current understanding of bacterial genome organization and demonstrates that a defined chromosomal structure is a universal feature of living systems., The research leading to these results was funded by the European Union Seventh Framework Programme (FP7/2007-2013 to L.S.), through the European Research Council, under grant agreement 232913 to L.S. and 609989 to M.A.M-R., the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 634942 to L.S, the Fundación Botín to L.S., the Spanish Ministry of Economy and Competitiveness (BIO2007-61762 to L.S. and BFU2013-47736-P to M.A.M.-R., the National Plan of R+D+i, the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación- (PI10/01702 to L.S.), the Human Frontiers Science Program (RGP0044 to M.A.M.-R.), the ERASynBio/MINECO Grant PCIN-2015-125 to L.S, and the European Regional Development Fund (ERDF) to L.S. We acknowledge support from the Spanish Ministry of Economy and Competitiveness, 'Centro de Excelencia Severo Ochoa 2013-2017' (SEV-2012-0208). We acknowledge the support of the CERCA Programme / Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

  • Garrido, Victoria
  • Piñero Lambea, Carlos
  • Rodriguez Arce, Irene
  • Paetzold, Bernhard
  • Ferrar, Tony
  • Weber, Marc
  • Garcia-Ramallo Pla, EVA
  • Gallo, Carolina
  • Collantes, María
  • Peñuelas, Ivan
  • Serrano, Luis
  • Grillo, Maria-Jesus
  • Lluch, Maria
This work has been supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac), and the LaCaixa Fundation grant (Livetherapeutics HR18-00058). M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Accion Estrat egica en Salud 2016) (reference CP16/00094). We also acknowledge the staff of CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) unit is a member of the ProteoRed PRB3 consortium, which is supported by grant PT17/0019 of the PE I + D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We also acknowledge Margarita Ecay for her assistance in the PET images analysis and Samuel Miravet-Verde for the bioinformatic support., Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo. We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro, ex vivo, and in vivo. To our knowledge, this is the first engineered genome-reduced bacterium that can fight against clinically relevant biofilm-associated bacterial infections., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineering a genome reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

  • Garrido, Victoria
  • Piñero Lambea, Carlos
  • Rodriguez Arce, Irene
  • Paetzold, Bernhard
  • Ferrar, Tony
  • Weber, Marc
  • Garcia Ramallo, Eva
  • Gallo López, Carolina
  • Collantes, María
  • Penuelas, Ivan
  • Serrano, Luis
  • Grillo, Maria-Jesus
  • Lluch, Maria
This work has been supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac), and the LaCaixa Fundation grant (Livetherapeutics HR18-00058). M.L.-S. acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Accion Estrat egica en Salud 2016) (reference CP16/00094). We also acknowledge the staff of CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) unit is a member of the ProteoRed PRB3 consortium, which is supported by grant PT17/0019 of the PE I + D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We also acknowledge Margarita Ecay for her assistance in the PET images analysis and Samuel Miravet-Verde for the bioinformatic support., Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo. We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro, ex vivo, and in vivo. To our knowledge, this is the first engineered genome-reduced bacterium that can fight against clinically relevant biofilm-associated bacterial infections., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development of a serum-free medium to aid large-scale production of mycoplasma-based therapies

  • Burgos, Raul
  • Garcia-Ramallo, Eva
  • Shaw, Daniel
  • Lluch-Senar, Maria
  • Serrano, Luis
This work has been supported by the European Union’s Horizon 2020 research and innovation program under grant agreement 634942 (MycoSynVac), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under grant agreement 670216 (MYCOCHASSIS), and Conveni La Caixa 2020-2023 (LA CAIXA-EGA, LCF/PR/GN13/10260009). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program from the Generalitat de Catalunya. We also acknowledge the staff of the CRG Genomics Unit for performing RNA-seq library preparation and sequencing. The proteomics analyses were performed in the CRG/UPF Proteomics Unit, which is part of the Proteored, PRB3, and is supported by grant PT17/0019 of the PE I1D1i 2013-2016, funded by ISCIII and ERDF. We also thank Jetta Bijlsma and Tjerko Kamminga for sharing the nonpathogenic J. strain of M. hyopneumoniae. Patent applications were filed for the M. pneumoniae (WO2021078935) and M. hyopneumoniae (WO2021078938) serum-free media. Luis Serrano and Maria Lluch-Senar are cofounders of Pulmobiotics Ltd., and Maria Lluch-Senar is currently an employee of this company., To assist in the advancement of the large-scale production of safe Mycoplasma vaccines and other Mycoplasma-based therapies, we developed a culture medium free of animal serum and other animal components for Mycoplasma pneumoniae growth. By establishing a workflow method to systematically test different compounds and concentrations, we provide optimized formulations capable of supporting serial passaging and robust growth reaching 60 to 70% of the biomass obtained in rich medium. Global transcriptomic and proteomic analysis showed minor physiological changes upon cell culture in the animal component-free medium, supporting its suitability for the production of M. pneumoniae-based therapies. The major contributors to growth performance were found to be glucose as a carbon source, glycerol, cholesterol, and phospholipids as a source of fatty acids. Bovine serum albumin or cyclodextrin (in the animal component-free medium) were required as lipid carriers to prevent lipid toxicity. Connaught Medical Research Laboratories medium (CMRL) used to simplify medium preparation as a source of amino acids, nucleotide precursors, vitamins, and other cofactors could be substituted by cysteine. In fact, the presence of protein hydrolysates such as yeastolate or peptones was found to be essential and preferred over free amino acids, except for the cysteine. Supplementation of nucleotide precursors and vitamins is not strictly necessary in the presence of yeastolate, suggesting that this animal origin-free hydrolysate serves as an efficient source for these compounds. Finally, we adapted the serum-free medium formulation to support growth of Mycoplasma hyopneumoniae, a swine pathogen for which inactivated whole-cell vaccines are available., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A genetic toolkit and gene switches to limit Mycoplasma growth for biosafety applications

  • Broto, Alicia
  • Gaspari, Erika
  • Miravet Verde, Samuel, 1992-
  • Martins dos Santos, Vitor
  • Isalan, Mark
Mycoplasmas have exceptionally streamlined genomes and are strongly adapted to their many hosts, which provide them with essential nutrients. Owing to their relative genomic simplicity, Mycoplasmas have been used to develop chassis for biotechnological applications. However, the dearth of robust and precise toolkits for genomic manipulation and tight regulation has hindered any substantial advance. Herein we describe the construction of a robust genetic toolkit for M. pneumoniae, and its successful deployment to engineer synthetic gene switches that control and limit Mycoplasma growth, for biosafety containment applications. We found these synthetic gene circuits to be stable and robust in the long-term, in the context of a minimal cell. With this work, we lay a foundation to develop viable and robust biosafety systems to exploit a synthetic Mycoplasma chassis for live attenuated vectors for therapeutic applications., This work was funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634942 (MycoSynVac)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Rescuing discarded spectra: full comprehensive analysis of a minimal proteome

  • Lluch-Senar, Maria 1982-
  • Mancuso, Francesco M.
  • Climente González, Héctor
  • Peña Paz, Marcia I.
  • Sabidó Aguadé, Eduard, 1981-
  • Serrano Pubull, Luis, 1982-
A common problem encountered when performing large-scale MS proteome analysis is the loss of information due to the high percentage of unassigned spectra. To determine the causes behind this loss we have analyzed the proteome of one of the smallest living bacteria that can be grown axenically, Mycoplasma pneumoniae (729 ORFs). The proteome of M. pneumoniae cells, grown in defined media, was analyzed by MS. An initial search with both Mascot and a species-specific NCBInr database with common contaminants (NCBImpn), resulted in around 79% of the acquired spectra not having an assignment. The percentage of non-assigned spectra was reduced to 27% after re-analysis of the data with the PEAKS software, thereby increasing the proteome coverage of M. pneumoniae from the initial 60% to over 76%. Nonetheless, 33 413 spectra with assigned amino acid sequences could not be mapped to any NCBInr database protein sequence. Approximately, 1% of these unassigned peptides corresponded to PTMs and 4% to M. pneumoniae protein variants (deamidation and translation inaccuracies). The most abundant peptide sequence variants (Phe-Tyr and Ala-Ser) could be explained by alterations in the editing capacity of the corresponding tRNA synthases. About another 1% of the peptides not associated to any protein had repetitions of the same aromatic/hydrophobic amino acid at the N-terminus, or had Arg/Lys at the C-terminus. Thus, in a model system, we have maximized the number of assigned spectra to 73% (51 453 out of the 70 040 initial acquired spectra)., This work was sup-ported by the European Research Council (ERC), the Fundación Marcelino Botín, the Spanish Ministerio de Economía y Com-petitividad BIO2007-61762 and the ISCIII (PI10/01702). TheCRG/UPF Proteomics Unit is part of the “Plataforma de Re-cursos Biomoleculares y Bioinform´aticos (ProteoRed)” supportedby grant PT13/0001 of Instituto de Salud Carlos III (ISCIII).We acknowledge the support of the Spanish Ministry of Economyand Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012-0208. This project has received funding fromthe European Union’s Horizon 2020 research and innovationprogram under grant agreement No 634942
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SynMyco transposon: engineering transposon vectors for efficient transformation of minimal genomes

  • Montero-Blay, Ariadna, 1994-
  • Miravet Verde, Samuel, 1992-
  • Lluch-Senar, Maria 1982-
  • Piñero-Lambea, Carlos
  • Serrano Pubull, Luis, 1982-
Mycoplasmas are important model organisms for Systems and Synthetic Biology, and are pathogenic to a wide variety of species. Despite their relevance, many of the tools established for genome editing in other microorganisms are not available for Mycoplasmas. The Tn4001 transposon is the reference tool to work with these bacteria, but the transformation efficiencies (TEs) reported for the different species vary substantially. Here, we explore the mechanisms underlying these differences in four Mycoplasma species, Mycoplasma agalactiae, Mycoplasma feriruminatoris, Mycoplasma gallisepticum and Mycoplasma pneumoniae, selected for being representative members of each cluster of the Mycoplasma genus. We found that regulatory regions (RRs) driving the expression of the transposase and the antibiotic resistance marker have a major impact on the TEs. We then designed a synthetic RR termed SynMyco RR to control the expression of the key transposon vector elements. Using this synthetic RR, we were able to increase the TE for M. gallisepticum, M. feriruminatoris and M. agalactiae by 30-, 980- and 1036-fold, respectively. Finally, to illustrate the potential of this new transposon, we performed the first essentiality study in M. agalactiae, basing our study on more than 199,000 genome insertions., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac) and was also financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We also acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms

  • Mazzolini, Rocco
  • Rodríguez-Arce, Irene
  • Fernández-Barat, Laia
  • Piñero-Lambea, Carlos
  • Garrido, Victoria
  • Rebollada-Merino, Agustín
  • Motos, Ana
  • Torres, Antoni
  • Grilló, María-Jesús
  • Serrano Pubull, Luis, 1982-
  • Lluch-Senar, Maria 1982-
Engineered live bacteria could provide a new modality for treating lung infections, a major cause of mortality worldwide. In the present study, we engineered a genome-reduced human lung bacterium, Mycoplasma pneumoniae, to treat ventilator-associated pneumonia, a disease with high hospital mortality when associated with Pseudomonas aeruginosa biofilms. After validating the biosafety of an attenuated M. pneumoniae chassis in mice, we introduced four transgenes into the chromosome by transposition to implement bactericidal and biofilm degradation activities. We show that this engineered strain has high efficacy against an acute P. aeruginosa lung infection in a mouse model. In addition, we demonstrated that the engineered strain could dissolve biofilms formed in endotracheal tubes of patients with ventilator-associated pneumonia and be combined with antibiotics targeting the peptidoglycan layer to increase efficacy against Gram-positive and Gram-negative bacteria. We expect our M. pneumoniae-engineered strain to be able to treat biofilm-associated infections in the respiratory tract., This work was supported by the European Research Council under the European Union’s Horizon 2020 research and innovation program, under grant agreement no. 670216 (MYCOCHASSIS). We thank the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program from the Generalitat de Catalunya, the European Union’s Horizon 2020 Research and Innovation Programme, grant no. 634942 (MycoSynVac), La Caixa Health (HR18-00058), CB 06/06/0028/CIBER de enfermedades respiratorias-Ciberes and ICREA Academy/Institució Catalana de Recerca i Estudis Avançats, 2.603/IDIBAPS, SGR/Generalitat de Catalunya for their support. M.L.-S. thanks the funder Instituto de Salud Carlos III (ISCIII, Acción Estratégica en Salud 2016, FEDER project, reference CP16/00094) for support of the research of this work. We also thank the staff of the CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies unit and a member of the ProteoRed PRB3 consortium, supported by grant no. PT17/0019 of the PE I+D+i 2013–2016 from the ISCIII and European Regional Development Fund.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Bacterial expression of a designed single-chain IL-10 prevents severe lung inflammation

  • Montero-Blay, Ariadna, 1994-
  • Delgado Blanco, Javier
  • Rodriguez-Arce, Irene
  • Lastrucci, Claire
  • Piñero-Lambea, Carlos
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that is active as a swapped domain dimer and is used in bacterial therapy of gut inflammation. IL-10 can be used as treatment of a wide range of pulmonary diseases. Here we have developed a non-pathogenic chassis (CV8) of the human lung bacterium Mycoplasma pneumoniae (MPN) to treat lung diseases. We find that IL-10 expression by MPN has a limited impact on the lung inflammatory response in mice. To solve these issues, we rationally designed a single-chain IL-10 (SC-IL10) with or without surface mutations, using our protein design software (ModelX and FoldX). As compared to the IL-10 WT, the designed SC-IL10 molecules increase the effective expression in MPN four-fold, and the activity in mouse and human cell lines between 10 and 60 times, depending on the cell line. The SC-IL10 molecules expressed in the mouse lung by CV8 in vivo have a powerful anti-inflammatory effect on Pseudomonas aeruginosa lung infection. This rational design strategy could be used to other molecules with immunomodulatory properties used in bacterial therapy., This work has been supported by the European Research Council (ERC) grant agreement 670216 (MYCOCHASSIS). We also acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Program from the Generalitat de Catalunya, the European Union's Horizon 2020 research and innovation programme under grant agreement 634942 (MycoSynVac). ML-S acknowledges the support of the FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016; reference CP16/00094). We also acknowledge the staff of CRG/UPF Proteomics Unit who is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) unit and is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CReasPy-Cloning: a method for simultaneous cloning and engineering of megabase-sized genomes in yeast using the CRISPR-Cas9 system.

  • Ruiz, Estelle
  • Talenton, Vincent
  • Dubrana, Marie-Pierre
  • Guesdon, Gabrielle
  • Lluch-Senar, Maria 1982-
  • Salin, Franck
  • Sirand-Pugnet, Pascal
  • Arfi, Yonathan
  • Lartigue, Carole
Over the past decade, a new strategy was developed to bypass the difficulties to genetically engineer some microbial species by transferring (or "cloning") their genome into another organism that is amenable to efficient genetic modifications and therefore acts as a living workbench. As such, the yeast Saccharomyces cerevisiae has been used to clone and engineer genomes from viruses, bacteria, and algae. The cloning step requires the insertion of yeast genetic elements in the genome of interest, in order to drive its replication and maintenance as an artificial chromosome in the host cell. Current methods used to introduce these genetic elements are still unsatisfactory, due either to their random nature (transposon) or the requirement for unique restriction sites at specific positions (TAR cloning). Here we describe the CReasPy-cloning, a new method that combines both the ability of Cas9 to cleave DNA at a user-specified locus and the yeast's highly efficient homologous recombination to simultaneously clone and engineer a bacterial chromosome in yeast. Using the 0.816 Mbp genome of Mycoplasma pneumoniae as a proof of concept, we demonstrate that our method can be used to introduce the yeast genetic element at any location in the bacterial chromosome while simultaneously deleting various genes or group of genes. We also show that CReasPy-cloning can be used to edit up to three independent genomic loci at the same time with an efficiency high enough to warrant the screening of a small (<50) number of clones, allowing for significantly shortened genome engineering cycle times., This work is part of the European MiniCell project “A model-driven approach to minimal cell engineering for medical therapy” selected by ANR, in the frame of the ERASynBio second Joint Call for Transnational Research Projects (No. ANR-15-SYNB-0001-04). It has also been supported by the National Science Foundation (Grant No. IOS-1110151) and the European Union’s Horizon 2020 research and innovation program under Grant Agreement No. 634942.